Alpha 2.0
Login Register
» Authors » Jason D Peterson

Jason D Peterson

Explore the profile of Jason D Peterson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 21
Citations 491
Followers 0
Related Specialties
Pathology
Biochemistry
Oncology
Top 10 Co-Authors
Gregory J Tsongalis
Francine B De Abreu
Christopher I Amos
Laura J Tafe
Arief A Suriawinata
Wendy A Wells
Konstantin H Dragnev
Xiaoying Liu
Jonathan D Marotti
Jason R Pettus
Published In
Exp Mol Pathol
Clin Chem Lab Med
Neoplasia
J Appl Lab Med
Hum Pathol
Affiliations
Soon will be listed here.
Recent Articles
1.
Rapid Somatic Mutation Testing in Colorectal Cancer by Use of a Fully Automated System and Single-Use Cartridge: A Comparison with Next-Generation Sequencing
Al-Turkmani M, Godwin K, Peterson J, Tsongalis G
J Appl Lab Med . 2021 Feb; 3(2):178-184. PMID: 33636938
Background: Molecular tests have been increasingly used in the management of various cancers as more targeted therapies are becoming available as treatment options. The Idylla™ system is a fully integrated,...
2.
Use of Biosynthetic Controls as Performance Standards for Next-Generation Sequencing Assays of Somatic Tumors: A Multilaboratory Study
De Abreu F, Peterson J, Deharvengt S, Daber R, Sarsani V, Spotlow V, et al.
J Appl Lab Med . 2020 Jul; 2(2):138-149. PMID: 32630970
Background: Next-generation sequencing (NGS) assays are highly complex tests that can vary substantially in both their design and intended application. Despite their innumerous advantages, NGS assays present some unique challenges...
3.
Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board
Bernhardt E, Chamberlin M, Gorlov I, De Abreu F, Bloch K, Peterson J, et al.
Pract Lab Med . 2020 Jul; 21:e00174. PMID: 32613070
Matching of actionable tumor mutations with targeted therapy increases response rates and prolongs survival in lung cancer patients. Drug development and trials targeting genetic alterations are expanding rapidly. We describe...
4.
Impact of Molecular Sequencing Information as Related to 2008 and 2016 World Health Organization Classification of Acute Myeloid Leukemia and Myelodysplasia
Toth L, De Abreu F, Peterson J, Loo E
Arch Pathol Lab Med . 2018 Aug; 142(9):1017. PMID: 30141999
No abstract available.
5.
Identifying Associations between Somatic Mutations and Clinicopathologic Findings in Lung Cancer Pathology Reports
Kumar N, Tafe L, Higgins J, Peterson J, de Abreu F, Deharvengt S, et al.
Methods Inf Med . 2018 Apr; 57(1):63-73. PMID: 29621832
Objective: We aim to build an informatics methodology capable of identifying statistically significant associations between the clinical findings of non-small cell lung cancer (NSCLC) recorded in patient pathology reports and...
6.
Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing
Shajani-Yi Z, De Abreu F, Peterson J, Tsongalis G
Neoplasia . 2018 Feb; 20(3):256-262. PMID: 29454261
The tumor suppressor gene TP53 is the most frequently mutated gene in human cancer. It encodes p53, a DNA-binding transcription factor that regulates multiple genes involved in DNA repair, metabolism,...
7.
Somatic mutation analysis in melanoma using targeted next generation sequencing
Miraflor A, De Abreu F, Peterson J, Turner S, Amos C, Tsongalis G, et al.
Exp Mol Pathol . 2017 Aug; 103(2):172-177. PMID: 28822769
Advanced stage malignant melanoma often responds poorly to therapy with low survival rates. New therapeutic approaches are based upon a growing understanding of the underlying molecular abnormalities. We demonstrate the...
8.
Variant call concordance between two laboratory-developed, solid tumor targeted genomic profiling assays using distinct workflows and sequencing instruments
Hampel K, De Abreu F, Sidiropoulos N, Peterson J, Tsongalis G
Exp Mol Pathol . 2017 Feb; 102(2):215-218. PMID: 28192086
Targeted genomic profiling (TGP) using massively parallel DNA sequencing is becoming the standard methodology in clinical laboratories for detecting somatic variants in solid tumors. The variety of methodologies and sequencing...
9.
Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing
Gardner J, Peterson J, Turner S, Soares B, Lancor C, Dos Santos L, et al.
Am J Clin Pathol . 2016 Oct; 146(4):448-55. PMID: 27686171
Objectives: To describe three methods used to screen for frameshift mutations in exon 9 of the CALR gene. Methods: Genomic DNA from 47 patients was extracted from peripheral blood and...
10.
Clinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes
Tafe L, Pierce K, Peterson J, De Abreu F, Memoli V, Black C, et al.
Neoplasia . 2016 Sep; 18(9):577-83. PMID: 27659017
Detection of somatic mutations in non-small cell lung cancers (NSCLCs), especially adenocarcinomas, is important for directing patient care when targeted therapy is available. Here, we present our experience with genotyping...